==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1446 details
Primary information
ThPP IDTh1079
Therapeutic Peptide/Protein NameSerum albumin
SequenceDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA view full sequnce in fasta
Functional ClassificationIV
Molecular Weight66472.2
Chemical FormulaC2936H4624N786O889S41
Isoelectric Point5.67
Hydrophobicity-0.395
Melting Point (℃)62
Half LifeN.A.
DescriptionSuspension of microspheres of human serum albumin with perflutren. Perflutren is a highly fluorinated small molecule, used to enhance contrast for ultrasound imaging procedures
Indication/DiseaseFor treatment of severe blood loss, hypervolemia, hypoproteinemia.
PharmacodynamicsSerum albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.
Mechanism of ActionSerum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It binds many other substances, such as unconjugated bilirubin, calcium ions, and other fat soluble hormones.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesSerum substitutes
Patents NumberUS5558094
Date of Issue01/03/99
Date of Expiry29/02/16
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameOptison
CompanyGE Healthcare
Brand DiscriptionOptison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is a sterile non-pyrogenic suspension of microspheres of human serum albumin with perflutren for contrast enhancement during the indicated ultrasound imaging procedures. The vial contains a clear liquid lower layer and a white upper layer that, after resuspension by gentle mixing, provides a homogeneous, opaque, milky-white suspension for Intravenous infusion. Perflutren is chemically characterized as 1,1,1,2,2,3,3,3-perflutren with a molecular weight of 188, an empirical formula of C3F8.
Prescribed forN.A.
Chemical NameN.A.
FormulationOptison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is available in a carton of five 3 mL fills in single use 3 mL vials. Each mL of Optison contains 5.0-8.0×108 protein-type A microspheres, 10 mg Albumin Human, USP, 0.22 ± 0.11 mg/mL perflutren, 0.2 mg N-acetyltryptophan, and 0.12 mg caprylic acid in 0.9% aqueous sodium chloride. The headspace of the vial is filled with perflutren gas. The pH is adjusted to 6.4-7.4. The protein in the microsphere shell makes up approximately 5-7% (w/w) of the total protein in the liquid.
Physcial AppearnceN.A.
Route of AdministrationIntravenous
Recommended DosageN.A.
ContraindicationRight-to-left, bi-directional, or transient right-to-left cardiac shunts, Hypersensitivity to perflutren, blood, blood products or albumin. Do not administer Optison by intra-arterial injection. This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral disease or CJD have ever been identified for albumin.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25895349, 25755577, 12846933, 9675210, 17667792
3-D StructureTh1079 (View) or (Download)